A 22-year-old male with a history of difficult-to-treat bipolar disorder with psychotic features is undergoing a medication adjustment under the guidance of his psychiatrist. The patient was previously treated with lithium and is transitioning to clozapine. Which of the following tests will the patient need routinely?

Thyroid-stimulating hormone, prior to introducing the medication

Dexamethasone suppression test, monthly

A 24-year-old man with a history of schizophrenia presents for follow-up. The patient says that he is still having paranoia and visual hallucinations on his latest atypical antipsychotic medication. Past medical history is significant for schizophrenia diagnosed 1 year ago that failed to be adequately controlled on 2 separate atypical antipsychotic medications. The patient is switched to a typical antipsychotic medication. Which of the following is the mechanism of action of the medication that was most likely prescribed for this patient?

Dopaminergic receptor antagonist

Serotonergic receptor antagonist

A 30-year-old man presents to his psychiatrist for a follow-up visit. He was diagnosed with schizophrenia 6 months ago and has been taking fluphenazine. He says that his symptoms are well controlled by the medication, and he no longer has auditory hallucinations. The psychiatrist also notes that his delusions and other psychotic symptoms have improved significantly. However, the psychiatrist notices something while talking to the patient that prompts him to say, “I know the drug has effectively controlled your symptoms but I think you should discontinue it now otherwise this side effect is likely to be irreversible.” Which of the following did the psychiatrist most likely notice in this patient?

Choreoathetoid movements of face

Crossing and uncrossing legs constantly

Involuntary sustained twisting of neck

Reduced spontaneous movements while walking

A 19-year-old female college student is brought into the emergency department by her boyfriend. The boyfriend reports that the patient got caught stealing from the company she works for and subsequently got fired. The boyfriend received a text that evening saying “I’ll miss you.” When he arrived at her dorm room, the patient was slumped in the shower covered in blood. The patient agreed to be driven to the emergency room. When asked about what happened, the patient replies “I just want out of this life.” The patient has bipolar disorder, and takes lithium as prescribed. She has a psychiatrist she sees every week, which the boyfriend confirms. She has never had a prior suicide attempt nor has she ever been hospitalized for a psychiatric disorder. The patient’s vitals are stable. Upon physical examination, a 4 centimeter vertical incision is noted on the patient’s left forearm. During the patient’s laceration repair, she asks if she will be admitted. She states, “these ups and downs are common for me, but I feel better now.” She verbalizes that she understands that she overreacted. She asks to go home, and her boyfriend insists that he will stay with her. They both confirm that neither of them have guns or know any peers with access to guns. Which of the following is the most appropriate management for the patient?

Involuntarily admit the patient

Have the patient sign a suicide contract before discharge

Set up a next-day appointment with the patient’s psychiatrist

Discontinue lithium and start valproate

A 26-year-old female college student is brought back into the university clinic for acting uncharacteristically. The patient presented to the same clinic 6 weeks ago with complaints of depressed mood, insomnia, and weightloss. She had been feeling guilty for wasting her parent’s money by doing so poorly at the university. She felt drained for at least 2 weeks before presenting to the clinic for the first time. She was placed on an antidepressant and was improving but now presents with elevated mood. She is more talkative with a flight of ideas and is easily distractible. Which of the following statements is most likely true regarding this patient’s condition?

Her diagnosis of unipolar depression is incorrect.

The patient may have psychotic features.

The patient may have a history of mania.

Antidepressants are inappropriate.

Her new symptoms need to last at least 7 days.

Antipsychotics in bipolar disorder for USMLE Step 3: High-Yield Psychiatry Lessons

Mechanism of Action - Dopamine's Dance

Primary Action: Central blockade of dopamine D₂ receptors.
- Mesolimbic Pathway: ↓ Dopamine activity controls positive symptoms (mania, psychosis).
- Nigrostriatal Pathway: D₂ blockade → Extrapyramidal Symptoms (EPS) like parkinsonism, akathisia.
- Tuberoinfundibular Pathway: D₂ blockade → ↑ Prolactin, causing gynecomastia, galactorrhea.
- Mesocortical Pathway: Can sometimes worsen negative symptoms.
Atypical (SGA) Advantage: Additional serotonin 5-HT₂ₐ receptor blockade.
- This action ↑ dopamine release in the nigrostriatal tract, reducing the risk of EPS.

Dopamine pathways: mesocortical, mesolimbic, nigrostriatal

⭐ Therapeutic efficacy requires ~60-75% D₂ receptor occupancy; EPS risk sharply rises at >80%.

Indications & Agents - The Right Tool

Acute Mania/Mixed Episodes: Used as monotherapy or adjunct to mood stabilizers (Lithium, Valproate) for rapid stabilization.
- Agents: Aripiprazole, Olanzapine, Quetiapine, Risperidone, Ziprasidone.
Bipolar Depression: Crucial for treating depressive episodes without inducing mania.
- Agents: Lurasidone, Quetiapine, Cariprazine, and the Olanzapine-Fluoxetine Combination (OFC) are FDA-approved.
Maintenance Therapy: Prevents recurrence. Long-acting injectables (LAIs) like Aripiprazole or Risperidone LAI boost adherence.

⭐ Lurasidone is notable for its efficacy in bipolar depression with a low risk of metabolic side effects and minimal weight gain, making it a favorable choice.

Adverse Effects - The Price of Stability

Metabolic Syndrome: Common with SGAs. Manifests as weight gain, dyslipidemia, and hyperglycemia.
- Highest risk: Olanzapine, Clozapine.
- Moderate risk: Risperidone, Quetiapine.
- Lower risk: Aripiprazole, Ziprasidone, Lurasidone.
- Monitoring: Check BMI, waist circumference, fasting glucose, and lipids at baseline and regularly.
Extrapyramidal Symptoms (EPS): Lower risk than FGAs but still present.
- Highest SGA risk with Risperidone, especially at doses >6 mg/day.
- Includes akathisia, parkinsonism, and dystonia.
- Tardive Dyskinesia (TD): A serious, long-term risk involving involuntary movements.
Other Key Effects:
- Hyperprolactinemia: Especially with Risperidone → gynecomastia, amenorrhea.
- Sedation: Prominent with Clozapine, Olanzapine, Quetiapine.
- ⚠️ Black Box Warning: Increased mortality in elderly patients with dementia-related psychosis.

⭐ For new-onset Tardive Dyskinesia, the standard of care is to treat with a VMAT2 inhibitor (e.g., valbenazine, deutetrabenazine) rather than just stopping the antipsychotic.

Antipsychotic Side Effects Chart

Clinical Monitoring - The Watchful Guardian

Baseline & Periodic Checks:
- Weight (BMI), blood pressure
- Fasting glucose or HbA1c
- Fasting lipid panel
Agent-Specific Monitoring:
- ECG: for QTc prolongation (ziprasidone)
- Prolactin: for hyperprolactinemia (risperidone)
- CBC: for agranulocytosis (clozapine)

Antipsychotic Medication Monitoring Schedule

⭐ All second-generation antipsychotics warrant vigilant screening for metabolic syndrome, a high-yield exam topic.

High-Yield Points - ⚡ Biggest Takeaways

Atypical antipsychotics (e.g., olanzapine, quetiapine) are first-line for acute mania, often combined with mood stabilizers.

Also used for maintenance therapy to prevent both manic and depressive episodes.

The most significant side effect is metabolic syndrome; regularly monitor BMI, glucose, and lipids.

Lower risk of extrapyramidal symptoms (EPS) than typicals, but tardive dyskinesia (TD) remains a concern.

Lurasidone and the olanzapine-fluoxetine combination are approved for bipolar depression.

Aripiprazole and ziprasidone carry a lower risk of metabolic side effects.

Continue reading on Oncourse

CONTINUE READING — FREE

or get the app

App Store|Google Play